Statins in COPD
| Autor: | J. Mark FitzGerald, Mahyar Etminan, Kirly Park, John R. Swiston, Surinder Janda |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Pulmonary and Respiratory Medicine
education.field_of_study medicine.medical_specialty COPD business.industry Population Retrospective cohort study Critical Care and Intensive Care Medicine medicine.disease respiratory tract diseases law.invention Pulmonary function testing FEV1/FVC ratio Randomized controlled trial law Internal medicine Physical therapy Medicine Observational study Cardiology and Cardiovascular Medicine business education Cohort study |
| Zdroj: | Chest. 136:734-743 |
| ISSN: | 0012-3692 |
| Popis: | Background The 3-hydroxy 3-methylglutaryl coenzyme A reductase inhibitors ( ie , statins) are widely used for the treatment of patients with hypercholesterolemia and cardiovascular disease. Emerging evidence suggests a beneficial effect of statins on the morbidity and mortality of patients with COPD. The objective of this study was to perform a systematic review of the literature evaluating the effect of statin therapy on outcomes in patients with COPD. Methods Medline, Excerpta Medica Database, PapersFirst, and the Cochrane collaboration and Cochrane Register of controlled trials were searched. Randomized controlled trials (RCTs), observational cohort studies, case-control studies, and population-based analyses were considered for inclusion. Results Nine studies were identified for review (four retrospective cohorts, one nested case-control study of a retrospective cohort, one retrospective cohort and case series, two population-based analyses, and one RCT). All studies showed a benefit from statin therapy for various outcomes in COPD patients, including the number of COPD exacerbations (n = 3), the number of and time to COPD-related intubations (n = 1), pulmonary function ( eg , FEV 1 and FVC) [n = 1], exercise capacity (n = 1), mortality from COPD (n = 2), and all-cause mortality (n = 3). No studies describing a negative or neutral effect from statin therapy on outcomes in COPD patients were identified. Conclusions The current literature collectively suggests that statins may have a beneficial role in the treatment of COPD. However, the majority of published studies have inherent methodological limitations of retrospective studies and population-based analyses. There is a need for prospective interventional trials designed specifically to assess the impact of statins on clinically relevant outcomes in COPD. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|